MEDİTERA

TIBBİ MALZEME SANAYİ VE TİCARET A.Ş.

2026 – H1 FINANCIAL RESULTS

Meditera Tıbbi Malzeme Sanayi ve Ticaret A.Ş. (“Meditera” or the “Company”) announced its 2026 first half results today.

Meditera registered TL 1,360 M revenues and TL 145 M EBITDA in the first half of 2026. Due to the negative impact of the inflationary environment on costs, EBITDA margin stood at 10.6% (H1 2025: 11.7%).



Details on Company’s financial and operational data data are provided below.

TL M	H1 2026	H1 2025	% Δ
Revenues	**1,360**	**1,659**	**(18%)**
Domestic Sales	413	634	(35%)
International Sales	947	1,025	(8%)
Gross Profit	458	533	(14%)
EBITDA	**145**	**195**	**(26%)**
Net Profit	(77)	(129)	n.m.
Gross Profit Margin (%)	33.7%	32.1%	1.6 pp
EBITDA Margin (%)	**10.6%**	**11.7%**	(1.1 pp)
Net Profit Margin (%)	(5.7%)	(7.8%)	n.m.

TL M	H1 2026	2025	% Δ
Cash & Cash Equivalents	484	455	6%
Net Cash	456	409	12%

FINANCIAL RESULTS

All data presented in the financial results part have been adjusted for inflation in accordance with TAS 29 "Financial Reporting in Hyperinflationary Economies".

The Company's sales revenues decreased 18% in the first half of 2026 compared to the first half of 2025. The share of the export revenues in total revenues was 70% in the first half of 2026 (H1 2025: 62%).

n the first half of 2026, EBITDA declined by 26% year on year to TL 145 M. The decline in EBITDA was primarily attributable to the impact of inflationary pressures on costs, as mentioned above, as well as the adverse effect of higher oil prices on operating costs. The impact of the salary increases implemented at the beginning of the year puts pressure particularly on first-quarter profitability, while this pressure gradually diminishes in the subsequent quarters. As a result of these factors, the Company recorded an EBITDA margin of 10.6% in the first six months of 2026.

The new factory investment of our Company, located within our production campus in Tire and comprising 13,140 m² of indoor space, has been commissioned and production activities are ongoing. With this investment, our cleanroom area has nearly doubled, while our production capacity has also increased. In addition, the size of our R&D center has been expanded to 793 m², further strengthening our product development capabilities.

The contribution of the product groups whose production has commenced at our new facility to sales revenue is expected to increase gradually. As previously stated, due to the time required for licensing, authorization and certification processes applicable in the healthcare sector, the commercial contribution of these new products is realized progressively. Our new products used in anesthesia, intensive care and home care are expected to broaden our existing product portfolio and support our value-added sales. Necessary disclosures will be made to the public upon completion of the certification processes for the final products.

In addition, within the scope of our rooftop solar power plant investments carried out at our production facility located in the Tire Organized Industrial Zone, a total installed capacity of 2,389.80 kWp has been reached over an area of 10,330 m². Thanks to our renewable energy investments, a significant portion of the Company's total electricity consumption is met through sustainable resources, contributing to the management of energy costs and the reduction of our carbon footprint.

Our company maintained its net cash position as of 30.06.2026 and recorded a net cash balance of TL 456 M, primarily driven by cash generated from its operations.

Based on the operating results of 2025, in line with the Board of Directors' resolution dated 06.03.2026, a gross cash dividend distribution proposal amounting to TRY 40.5 million, corresponding to 28.93% of the issued share capital, was prepared. Said proposal was approved at the Ordinary General Assembly Meeting held on 02.04.2026.

During the first half of 2026, our sales activities continued in both domestic and export markets, while tenders and commercial opportunities in the public and private sectors were closely monitored. While expanding its operational scale, our Company continues to maintain a balance between cash flow, profitability, efficiency and sustainable growth.

Our goal for the upcoming period is to continue being a company that grows steadily through its innovative product portfolio, increasing production capacity, strong financial structure and high export potential, while creating value for its investors and sharing such value in a sustainable manner.

ABOUT MEDİTERA

The first establishment of our company was founded in 1983 by Atilla Sevinçli, who is a pharmacits, in Izmir in 1983 and took its place among the leading medical equipment companies in the sector in the 90s.

Meditera is specialized in the production of anesthesia and intensive care breathing circuits, installation, operation and project design of oncology medicine preparation and implementation systems, distributorship, production and technical service of infusion pumps and sets as well as biocidal product production.

In addition, S & Mohr, 20% subsidiary of the Company established as a joint venture with Internacional Farmacéutica S.A. de C.V. (IFSA), manufactures surgical sutures in its facilities in Turkey and S&Mohr America, 60% subsidiary of the Company, manufactures respiratory circuits and accessories in its facilities in Mexico.

On the back of its high quality approach, our company produces for well-known global brands and exports to more than 100 customers in more than 80 countries under the Altech brand.

As of June 30, 2026, Meditera registered TL 1,360 M sales revenues and TL 4,024 M assets. The company's shares have been traded on Borsa Istanbul under the ticker "MEDTR" since July 2021. For more information, please contact https://www.meditera.com.tr/ or contact the Investor Relations Department.

For further information

Meditera Investor Relations

Tel: +90 232 237 59 49

E-mail: yatirimci@meditera.com.tr